|
Report No. : |
325343 |
|
Report Date : |
05.06.2015 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIO HOSPIFARMA CHILE LTDA. |
|
|
|
|
Registered Office : |
Américo Vespucio 1385 Santiago, Quilicura XIII Metropolitana de Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
11.02.2011 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Import and wholesale of pharmaceutical items. |
|
|
|
|
No. of Employees : |
3 Employees |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made on
e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Chile |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE - ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports of goods and services account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2013, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Growth slowed to 4.2% in 2014. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and 10 other countries in negotiating the Trans-Pacific Partnership trade agreement. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD. In 2014, President Michelle BACHELET introduced tax reforms aimed at delivering her campaign promise to fight inequality and to provide access to education and health care. The reforms are expected to generate additional tax revenues equal to 3% of Chile’s GDP, mostly by increasing corporate tax rates to OECD averages.
|
Source
: CIA |
|
Legal Name: |
LABORATORIO HOSPIFARMA CHILE LTDA. |
|
Trade Name: |
HOSPIFARMA |
|
RUT: |
76.133.312-7 |
|
Date Created: |
2011 |
|
Date Incorporated: |
11/02/2011 |
|
Legal Address: |
Américo Vespucio 1385 Santiago, Quilicura XIII Metropolitana de
Santiago, Chile |
|
Operative Address: |
Américo Vespucio 1385 Santiago, Quilicura XIII Metropolitana de
Santiago, Chile |
|
Telephone: |
(562) 2337 4400 |
|
Fax: |
(562) 2663 9305 |
|
Legal Form: |
Limited Company |
|
Email: |
|
|
Registered in: |
Chile |
|
Website: |
|
|
Contact: |
Jariel Meliz Torren |
|
Staff: |
3 |
|
Activity: |
Pharmaceutical Wholesale |
|
Santander Rio |
|
|
|
The company does not make its banking data public |
The company was established in 2011
|
PRINCIPAL ACTIVITY |
The company is dedicated to the import and wholesale of pharmaceutical
ítems. |
|
Products/Services description: |
Terbinafine |
|
Brands: |
EXTRACAL |
|
Clients: |
Pharmaceutical Industry The company also files for Government Bids. |
|
Suppliers: |
NA |
|
Operations area: |
National |
|
The company imports from |
India, Pakistan |
|
The company exports to |
No exports |
|
The subject employs |
3 employees |
|
Payments: |
No Complaints |
|
Headquarters : |
Américo Vespucio 1385 Santiago, Quilicura XIII Metropolitana de
Santiago, Chile |
|
Branches: |
The company does not have branches |
|
Industry: |
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders %: |
This is a private company. We culd not confirm major holders. |
|
Management: |
Jariel Meliz Torren, Legal Representative |
|
Related Companies: |
Farmacéutica Caribean Ltda., Jariel Meliz Torren is related to this
company. |
|
The company does not make its financial statements public. |
|
|
|
There are no financial connected to the subject. |
There are no legal connected to the subject
The company is dedicated to the import and wholesale of pharmaceutical
ítems.
It has only 3 years of experience in the country and a small sized
structure. It has a quite low commercial profile.
The company mainly imports from India and Pakistan and distributes
nationally, also filing for government bids.
The company shows a low debt amount and is registered at the Chilean
Registry of Health Companies.
|
DEBTS |
$ 90.440 |
|
PAYMENTS |
No Complaints |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
NAME |
NA |
|
POSITION |
Receptionist |
|
COMMENTS |
She confirmed address and activity. She transferred our call to
the manager but we recahed his voicemail. We left a message asking to return
our call. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.64.18 |
|
|
1 |
Rs.98.30 |
|
Euro |
1 |
Rs.72.25 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
VNT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.